Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Roche,Bevacizumab,"Metastatic colorectal cancer , neoadjuvant treatment for metastatic disease confined to the liver",Bevacizumab (Avastin),Options for investment,Community and Hospital,Oncology Agents and Immunosuppressants
